Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004,...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of WVE is 21 and suggests 55% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell